Key Takeaways
- CDTI raised $12.0M (Series A) from Invivo Partners, Columbus Venture Partners (VP), CDTI.
- Sector: Healthcare Healthtech & Medtech.
- Geography: Spain.
Analysis
Spain's Integra Therapeutics, a forerunner in the development of advanced gene writing tools designed to enhance the efficacy, precision, and safety of advanced therapies, recently announced the completion of its €10.7 million pre-Series A funding round.
The investment round included new investors such as the EIC Fund, the venture capital division of the European Innovation Council (EIC) with the European Investment Bank (EIB) as the recorded investor, which invested €4 million. Additionally, CDTI Innvierte from the Spanish Ministry of Science, Innovation and University also participated with a contribution of €2.7 million.
Besides the new investors, existing investors such as AdBio Partners, Columbus Venture Partners, Invivo Partners, and Takeda Ventures also continued to demonstrate their support for Integra's vision.
The newly acquired funds will be used to incorporate fresh advancements into the FiCAT gene writing platform. They will also aid in the validation of various next-generation CAR-T therapies during the preclinical phase. Additionally, the funds will be utilized to expand the FiCAT cell engineering capabilities, thereby facilitating technology transfer to the pharmaceutical industry. The company had earlier announced promising preclinical data for its FiCAT platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in May.
Integra is also working on its inaugural gene therapy for a rare pediatric liver disease. This project is funded by an EIC Accelerator grant.
Avencia Sánchez-Mejías, PhD, CEO, and Co-Founder of Integra Therapeutics, expressed her gratitude towards the investors for their support. She stated that their support pushes the company closer to transforming the treatment of complex diseases like cancer, autoimmune diseases, and rare diseases. She further added that Integra continues to lead innovation in cell and gene therapies.
Chair of the EIC Fund Board, Svetoslava Georgieva, announced their investment in Integra Therapeutics and expressed confidence in the company's potential to develop groundbreaking therapies that could transform lives and advance the field of gene therapy globally.